Actively Recruiting

Phase 3
Age: 18Years - 100Years
All Genders
Healthy Volunteers
NCT05851508

The Effecttiveness of Intratympanic Methylprednisolon Injections Compared to Placebo in the Treatment of Vertigo Attacks in Meniere's Disease

Led by Leiden University Medical Center · Updated on 2023-12-04

148

Participants Needed

1

Research Sites

174 weeks

Total Duration

On this page

Sponsors

L

Leiden University Medical Center

Lead Sponsor

Z

ZonMw: The Netherlands Organisation for Health Research and Development

Collaborating Sponsor

AI-Summary

What this Trial Is About

Ménière's disease is an inner ear disorder in which patients suffer from attacks of vertigo, tinnitus and hearing loss. To date, it is unclear what the best treatment for this condition is. Giving injections in the inner ear with the adrenal cortical hormone methylprednisolone is a treatment that is already widely used, but still there is insufficient evidence in the effectiveness of this treatment. This multicenter trial compares a patient group which receives injections of methylprednisolone to a patient group which receives placebo injections. Subsequently, dizziness, tinnitus, hearing loss and quality of life will be assed and compared for the above mentioned groups, over a period of one year.

CONDITIONS

Official Title

The Effecttiveness of Intratympanic Methylprednisolon Injections Compared to Placebo in the Treatment of Vertigo Attacks in Meniere's Disease

Who Can Participate

Age: 18Years - 100Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults over 18 years old
  • Diagnosis of unilateral, definite Meniere's disease based on established criteria including two or more spontaneous vertigo episodes lasting 20 minutes to 12 hours
  • Audiometrically documented low- to medium-frequency sensorineural hearing loss in one ear
  • Fluctuating ear symptoms such as hearing loss, tinnitus, or fullness in the affected ear
  • Experienced 4 or more vertigo attacks in the last 6 months
  • Willing to follow daily trial medication and attend follow-up assessments
Not Eligible

You will not qualify if you...

  • Diagnosis of bilateral Meniere's disease
  • Severe disability or serious illness that could interfere with treatment or follow-up
  • Other active neuro-otologic disorders mimicking Meniere's disease (e.g., vestibular migraine, recurrent vestibulopathy, phobic postural vertigo, vertebro-basilar TIAs, acoustic neuroma)
  • Otitis media with effusion as shown by tympanogram
  • Intratympanic corticosteroid injections within the past 6 months
  • Previous intratympanic gentamicin injections or ear surgery for Meniere's disease
  • Pregnant or nursing women

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Leiden University Medical Centre

Leiden, South Holland, Netherlands, 2300RC

Actively Recruiting

Loading map...

Research Team

M

Maud Boreel, MD

CONTACT

B

Babette van Esch, MD, PHD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

The Effecttiveness of Intratympanic Methylprednisolon Injections Compared to Placebo in the Treatment of Vertigo Attacks in Meniere's Disease | DecenTrialz